A new method for delivering cellular therapies using electroporation
Adaptable and scalable electroporation for cellular therapy
This study is working on a new way to help treat blood cancers like acute lymphoblastic leukemia by improving how we get helpful genes into T cells, which could lead to safer and more effective CAR-T therapies for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cytequest, INC. NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project ID | NIH-11006102 on NIH RePORTER |
What this research studies
This research focuses on developing a flexible and scalable electroporation platform for cellular therapies, particularly for treating hematological cancers like acute lymphoblastic leukemia. The approach aims to improve the delivery of genetic material into T cells without the drawbacks associated with viral vectors, such as lengthy manufacturing times and potential safety issues. By utilizing electroporation, the researchers hope to enhance the efficiency and reproducibility of cell therapy production, making it more accessible for clinical applications. Patients may benefit from more effective and safer CAR-T therapies as a result of this innovative technology.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute lymphoblastic leukemia or other hematological cancers who may benefit from advanced cellular therapies.
Not a fit: Patients with solid tumors or those who do not have hematological cancers may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer CAR-T therapies for patients with certain types of blood cancers.
How similar studies have performed: Other research has shown promise in using electroporation for cell therapy, indicating that this approach could be a viable alternative to traditional methods.
Where this research is happening
Ithaca, United States
- Cytequest, INC. — Ithaca, United States (Active)
Researchers
- Principal investigator: Craighead, Harold G — Cytequest, INC.
- Study coordinator: Craighead, Harold G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.